Valuation models
price $294.89 · as of Nov 2, 2026
DCF · Perpetuity growth · 5yused294.35 – 536.57382.0723% undervaluedDCF · Perpetuity growth · 10y316.66 – 565.32406.9128% undervaluedDCF · EBITDA exit · 5y317.63 – 348.58332.6811% undervaluedDCF · EBITDA exit · 10y335.73 – 396.22364.5319% undervaluedP/E · peers162.14 – 325.46186.4258% overvaluedP/E · own history188.05 – 702.40507.6242% undervaluedPEG—347.8415% undervaluedEV/EBITDA · peers103.60 – 216.61131.62124% overvaluedEV/Revenue · peers152.83 – 382.11205.0844% overvaluedEarnings power value57.73 – 112.5578.93274% overvaluedDividend discount158.29 – 451.50250.2718% overvaluedWall St. consensus target—300.002% belowCost of capital (WACC)—6.63%—
DCF · Perpetuity growth · 5y leads for a mature, steady company — positive operating income and three years of positive free cash flow. How the headline model is chosen.
Model value · DCF · Perpetuity growth · 5y
382.07
AbbVie closed at $294.89 — undervalued by 23% vs model.
294.35the model's range536.57
DCF · Perpetuity growth · 5y leads for a mature, steady company — positive operating income and three years of positive free cash flow. From a five-year discounted cash flow.
Other models
78.93 – 507.62
Wall St. target
300.00 2% below
Below model, 1y
4 of 31 days
How it is valued
Valued asMature & stable
Low/slowing growth (~6% recent)Moderate margins (7% net margin)Pays dividendsHighly cyclical earningsHigh leverage (D/E 5.0x)
Model estimates for research reference only, not investment advice. Every model rests on assumptions that may not match what happens; how each model works is in the manual.